Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Peripheral Vascular Disease
Interventions: Fibrin sealant (FS2); Drug
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 13
States / cities: Jacksonville, Florida • Miami, Florida • Springfield, Illinois + 9 more

Conditions: Burns, Growth Hormone Treatment
Interventions: Somatropin, 0.09% Saline Solution; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 85 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diabetic Peripheral Neuropathy, Nerve Pain
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 40 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Norfolk, Virginia

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: FDG-PET, ASL-MRI, Lumbar Puncture; Drug · Other · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years to 89 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Myelomonocytic Leukemia
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cough
Interventions: CRP point of care testing; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions: Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 51
States / cities: Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,021 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more

Conditions: Breast Cancer Survivors
Interventions: Assessments, Assessment (Survivors Only), APOE and DNA Isolation; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years to 80 Years · Female only
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Congenital Heart Defects
Interventions: Triostat, Placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 5 Months
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • Seattle, Washington

Conditions: Acromegaly
Interventions: ONO-5788, ONO-5788 Placebo, Octreotide; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes Mellitus
Interventions: Exenatide, Exenatide matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more

Conditions: Multiple Myeloma
Interventions: Uproleselan, Placebo, Melphalan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Migraine
Interventions: Erenumab, Placebo, PACAP-38 Challenge Agent; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Obesity, Impaired Glucose Tolerance
Interventions: exenatide, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, HIV
Interventions: IL-7; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autoimmune Autonomic Ganglionopathy (AAG)
Interventions: Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Bethesda, Maryland • Boston, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Choroidal Neovascularization, Age-related Macular Degeneration
Interventions: hI-con1, ranibizumab, Sham injection; Biological · Other
Lead sponsor: Iconic Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 48
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more

Conditions: Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
Interventions: QRX-3; Drug
Lead sponsor: Ebima Clifford Okundaye; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pasedena, Texas

Conditions: Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Interventions: Acetylcholine, Insulin aspart; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Clostridium Difficile Infection
Interventions: SMT19969, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more

Conditions: Atopic Dermatitis
Interventions: Oral DS107, Placebo; Drug
Lead sponsor: Dignity Sciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Arlington Heights, Illinois • West Dundee, Illinois • Warren, Michigan + 5 more

Conditions: Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions: Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo; Dietary Supplement
Lead sponsor: Quantec Ltd; Industry
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hidradenitis Suppurativa
Interventions: Bermekimab, Adalimumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more

Search by objective public record fields.

Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients

The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy

Arterial Spin Labeling (ASL) MRI for Cognitive Decline

The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia

C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)

Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment

Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Oral DS107 in Moderate to Severe Atopic Dermatitis

Immune Defense Protein Impact On Respiratory Immune Outcomes

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa